Discover an innovative webinar delving into the use of cyclodextrins in parenteral drugs. Parenteral injection is often the best administration route for some active pharmaceutical ingredients. Developing these formulations is a complex task that requires safe, functional, high-quality ingredients. Cyclodextrins are excipients that enable parenteral drug development by increasing their aqueous solubility, increasing their chemical stability and improving their bioavailability through the formation of drug-cyclodextrin complexes.
Their usage in parenteral drug formulations is frequently preferred over other solubilizing techniques due to their favorable toxicological and pharmacokinetic profiles.
This webinar will demonstrate how to use cyclodextrins in parenteral applications, and how to address various formulation hurdles while highlighting their unique functionality that can propel research and development (R&D) efforts in a new direction.
Join this webinar to gain insights into cyclodextrins in parenteral drugs and the mechanisms of drug-cyclodextrin complex formation.
Firas El-Saleh, PhD, Principal Scientist, Pharmaceuticals, Life Sciences, Ashland
Dr. Firas El-Saleh has more than 25 years of experience in the pharmaceutical industry with a focus on oral solid dosage forms. He has co-authored more than 20 scientific articles, book chapters and posters about sustained release, drug solubility using solid dispersions technology, and the formation of cyclodextrin complexes. Dr. El-Saleh studied pharmacy at the University of Damascus in Syria and holds a PhD in Pharmaceutical Technology from the University of Kiel in Germany.
Cory Mahnen, Technology Team Leader, Parenterals, Life Sciences, Ashland
Cory Mahnen has more than 10 years of experience working in complex parenteral product and process development for a handful of CDMOs, focusing primarily on long-acting injectables (LAIs) utilizing PLGA in the form of nanoparticles, microparticles and in situ depots. Several of his papers have been published in peer-reviewed journals. Cory holds a BS and Masters in biology from Kent State University.
Who Should Attend?
This webinar will appeal to professionals in the following fields:
- Research and development
- New product development
- Principal Scientists
- Business development
- Process Engineer
- Project management/pilot plant
- Pharma manufacturing
What You Will Learn
Attendees will gain insights into:
- A regulatory overview of considerations for safe parenteral administration
- Important physiochemical and biological properties of cyclodextrins for intravenous administration
- Mechanisms of drug-cyclodextrin complex formation
- A rational step-by-step approach to optimizing drug solubilization and stabilization in parenteral formulations
Ashland’s pharma business is well known for acetylenics, cellulosics, and film coatings, and their polymers have a rich and diverse history supporting active pharmaceutical ingredient delivery. Deploying resources to build on their existing high impact and high value technologies, they are widening their portfolio of cellulose-based polymers (HPMC, HPC, CMC, HEC, EC), growing their excipient portfolio for injectables/biologics, including the possibility for customization, and they’re focusing on film coatings that live up to customer needs.